A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

NCT07644559 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
G12D Mutated KRAS

Interventions

DRUG: VS-7375
DRUG: cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)

Sponsor

Verastem, Inc.